PD 198306

Research use only, not for human use.

PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.

PD 198306 is a selective inhibitor of MAPK/ERK-kinase (MEK) with antihyperalgesic effects. PD 198306 reduces the Streptozocin-induced increase in the level of active ERK1.(In Vitro):PD 198306 (10?μM) reduces Tha-Crimson replication by 30% at 18?h and 50% at 36?h. PD 198306 (10? μM) significantly inhibits Tha-GFP replication by 25%.(In Vivo):In male Sprague Dawley rats bearing neuropathic pain, PD 198306 (1-30 μg/10 μL; i.t.) dose-dependently blocks static allodynia in both the chronic constriction injury and the streptozocin models.

PD198306 significantly inhibits Tha-GFP replication by 25% at 10?μM, after 36?h.PD198306 (5?μM) reduces Tha-Crimson replication significantly by 20% at 18?h but such a result could not be confirmed at 36?h. Cell Cycle Analysis Cell Line:Human induced pluripotent stem cells (iPSC) Concentration:10? μM Incubation Time:6? hours Result:Inhibited Tha-Crimson replication at 10?μM, reducing it by 30% at 18?h and 50% at 36?h.

Intrathecal administration of PD 198306 (1-30 μg per 10 μL) dose-dependently (1-30 μg) blocks static allodynia in both the streptozocin and the chronic constriction injury (CCI) models of neuropathic pain. Animal Model:Male Sprague Dawley rats (250-300 g) bearing neuropathic pain Dosage:1-30 μg per 10 μL and 3 mg per 100 μL (PD 198306 is suspended in cremophor:ethanol:water, 1 : 1 : 8.)Administration:Single doses of intrathecal (i.t.) or intraplantar (ipl) of PD 198306 (1-30 μg per 10 μL and 3 mg per 100 μL respectively Result:Intrathecal administration dose-dependently (1-30 μg) blocked static allodynia the streptozocin model of neuropathic pain. The minimum effective doses (MED) of 3 μg significantly blocked static allodynia 30 min after treatment. Both 10 μg and the highest dose used (30 μg) totally blocked the maintenance of static allodynia, for up to 1 h.

——

MAPK/ERK Signaling

MEK

Acidic mammalian chitinase (AMCase)|Bacterial|GH18 chitinase

——

——

212631-61-3

476.23

C18H16F3IN2O2

>98% (HPLC)

——

O=C(NOCC1CC1)C2=CC(F)=C(F)C(F)=C2NC3=CC=C(I)C=C3C

——

(-20℃)

With Ice Pack

≥ 2 years